BioNTech is a German biotechnology company known for its focus on developing personalized immunotherapies for cancer and infectious diseases. Founded in 2008, it gained international prominence for its collaboration with Pfizer to produce one of the first COVID-19 vaccines using mRNA technology. BioNTech’s innovative approach involves using the body’s own immune system to recognize and attack cancer cells, aiming to provide targeted treatments that can be tailored to individual patients. The company’s advancements in mRNA technology and vaccine development have positioned it as a key player in the biopharmaceutical industry.
BioNTech is undergoing a transformative phase with a notable revenue contraction in Q4 2024, though it exceeded market expectations. Despite a sharp decline in profit, BioNTech’s earnings per share surpassed…